Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Long-term surviving cancer patients as a source of therapeutic TCR.

Tytuł :
Long-term surviving cancer patients as a source of therapeutic TCR.
Autorzy :
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. .
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 May; Vol. 69 (5), pp. 859-865. Date of Electronic Publication: 2020 Jan 08.
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-
MeSH Terms :
Cancer Survivors*
CD4-Positive T-Lymphocytes/*transplantation
Immunotherapy, Adoptive/*methods
Neoplasms/*therapy
Receptors, Antigen, T-Cell/*isolation & purification
CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; Cancer Vaccines/administration & dosage ; Clinical Trials as Topic ; Histocompatibility Antigens Class II/immunology ; Humans ; Immunotherapy, Adoptive/trends ; Neoplasms/blood ; Neoplasms/immunology ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism
References :
Cancer Res. 2016 Apr 15;76(8):2087-93. (PMID: 27197251)
Clin Cancer Res. 2015 Mar 1;21(5):1019-27. (PMID: 25538264)
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10702-E10711. (PMID: 30348802)
Front Immunol. 2017 Nov 15;8:1564. (PMID: 29187853)
Blood. 2013 Jun 13;121(24):4894-901. (PMID: 23641014)
Clin Cancer Res. 2008 Jan 1;14(1):4-7. (PMID: 18172245)
J Immunol. 2018 Feb 1;200(3):1088-1100. (PMID: 29288199)
J Exp Med. 2010 Mar 15;207(3):651-67. (PMID: 20156973)
Clin Cancer Res. 2011 Jul 1;17(13):4568-80. (PMID: 21586625)
Mol Ther. 2018 Jul 5;26(7):1855-1866. (PMID: 29807781)
Oncoimmunology. 2019 Jan 11;8(3):1558663. (PMID: 30723591)
J Exp Med. 2010 Mar 15;207(3):637-50. (PMID: 20156971)
Nat Commun. 2019 May 7;10(1):2087. (PMID: 31064990)
Cytotherapy. 2011 May;13(5):629-40. (PMID: 21174490)
Nat Rev Immunol. 2018 Oct;18(10):635-647. (PMID: 30057419)
Immunity. 2013 Nov 14;39(5):846-57. (PMID: 24120362)
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8862-7. (PMID: 12853579)
Cancer Immunol Immunother. 2006 Dec;55(12):1553-64. (PMID: 16491401)
Oncoimmunology. 2017 Dec 26;7(4):e1412029. (PMID: 29632724)
Sci Rep. 2015 Oct 08;5:14896. (PMID: 26447332)
Int J Cancer. 2010 Jul 15;127(2):249-56. (PMID: 20178101)
Science. 1995 Jun 2;268(5215):1336-8. (PMID: 7761852)
Cancer Res. 2016 May 1;76(9):2540-51. (PMID: 27197263)
Nat Rev Clin Oncol. 2017 Feb;14(2):115-128. (PMID: 27245281)
Sci Transl Med. 2013 Aug 7;5(197):197ra103. (PMID: 23926201)
J Clin Oncol. 2011 Mar 1;29(7):917-24. (PMID: 21282551)
Nat Med. 2015 Aug;21(8):914-921. (PMID: 26193344)
Clin Cancer Res. 2017 Aug 1;23(15):4347-4353. (PMID: 28377481)
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6973-8. (PMID: 23576742)
Cancer Immunol Immunother. 2011 Jun;60(6):809-18. (PMID: 21365467)
PLoS Biol. 2010 Sep 14;8(9):. (PMID: 20856903)
Nat Med. 2019 Sep;25(9):1408-1414. (PMID: 31477906)
Br J Cancer. 2006 Dec 4;95(11):1474-82. (PMID: 17060934)
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819831068. (PMID: 30798772)
J Clin Oncol. 2017 Oct 10;35(29):3322-3329. (PMID: 28809608)
Cancer Immunol Immunother. 2019 Aug;68(8):1235-1243. (PMID: 31214732)
J Exp Med. 1998 Jan 19;187(2):265-70. (PMID: 9432985)
Oncoimmunology. 2017 Mar 17;6(4):e1302631. (PMID: 28507809)
Nat Med. 2019 Jun;25(6):947-953. (PMID: 31011207)
Nat Rev Cancer. 2016 Aug 23;16(9):566-81. (PMID: 27550819)
Oncoimmunology. 2012 Aug 1;1(5):670-686. (PMID: 22934259)
Science. 2014 May 9;344(6184):641-5. (PMID: 24812403)
Immunol Rev. 2019 Jul;290(1):39-59. (PMID: 31355492)
J Immunother. 2010 Oct;33(8):780-8. (PMID: 20842059)
EBioMedicine. 2019 Feb;40:106-117. (PMID: 30665853)
Clin Cancer Res. 2011 Nov 1;17(21):6847-57. (PMID: 21918169)
J Immunol. 2010 Jun 1;184(11):6232-41. (PMID: 20427762)
J Immunother. 2013 Feb;36(2):133-51. (PMID: 23377668)
Cancer Immunol Immunother. 2013 Sep;62(9):1499-509. (PMID: 23817721)
Blood. 2013 Aug 8;122(6):863-71. (PMID: 23770775)
Drug Saf. 2019 Feb;42(2):315-334. (PMID: 30649750)
Semin Cancer Biol. 2012 Feb;22(1):14-22. (PMID: 22210183)
Sci Transl Med. 2019 Jun 5;11(495):. (PMID: 31167925)
Cancer Biol Ther. 2007 Dec;6(12):1991-6. (PMID: 18087213)
N Engl J Med. 2008 Jun 19;358(25):2698-703. (PMID: 18565862)
Grant Information :
244388 Norges Forskningsråd; 254817 Norges Forskningsråd; 2017075 Norwegian Health Region South East; 2016006 Norwegian Health Region South East
Contributed Indexing :
Keywords: Adoptive cell therapy; CD4 T cells; Cancer immunotherapy; PIVAC 19; T cell receptor; Vaccination
Substance Nomenclature :
0 (Cancer Vaccines)
0 (Histocompatibility Antigens Class II)
0 (Receptors, Antigen, T-Cell)
Entry Date(s) :
Date Created: 20200110 Date Completed: 20200508 Latest Revision: 20200508
Update Code :
20210210
PubMed Central ID :
PMC7183495
DOI :
10.1007/s00262-019-02468-9
PMID :
31915853
Czasopismo naukowe
We have established a platform for the isolation of tumour-specific TCR from T cells of patients who experienced clinical benefit from cancer vaccination. In this review we will present the rationale behind this strategy and discuss the advantages of working with "natural" wild type TCRs. Indeed, the general trend in the field has been to use various modifications to enhance the affinity of such therapeutic TCRs. This was done to obtain stronger T cell responses, often at the cost of safety. We further describe antigen targets and recent in vitro and in vivo results obtained to validate them. We finally discuss the use of MHC class II-restricted TCR in immunotherapy. Typically cellular anti-tumour immune responses have been attributed to CD8 T cells; however, we isolated mainly CD4 T cells. Importantly, these MHC class II-restricted TCRs have the potential to induce broad, long lasting immune responses that enable cancer control. The use of CD4 T cell-derived TCRs for adoptive immunotherapy has so far been limited and we will here discuss their therapeutic potential.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies